← Oncology Approval Tracker

FDA DECISION ·

Avmapki Fakzynja Co-pack

avutometinib + defactinib · Verastem

Accelerated approvalNew therapyLow-grade serous ovarian cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with recurrent low-grade serous ovarian cancer harboring a KRAS mutation after prior systemic therapy.

LAMPGEN ANALYSIS

Why it matters

Dual RAF/MEK and FAK pathway inhibition created a targeted option in a rare ovarian cancer subtype; clinical benefit requires confirmation.

What research teams should watch

Verify low-grade serous histology and KRAS status, then explain the distinct schedules of the two oral agents.

PRIMARY RECORDS

Sources